By: Susan Gubar
The Broadway star Marin Mazzie brings the same exuberance to living with late-stage ovarian cancer that she displays in her performances. Or perhaps the roles she has undertaken in musicals like “Ragtime,” “Kiss Me Kate” and “The … Read more
For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are … Read more
With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more
Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer. A multi-centre clinical trial has demonstrated that CT Perfusion, which measures blood … Read more
British biotech company Angle has unveiled the trial results of a potential breakthrough blood test for diagnosing ovarian cancer.
The test could lead to quicker diagnosis and referrals for women with malignant tumours to specialist surgeons.
Angle, an AIM-listed liquid … Read more
By: Annette McElhiney
In 1953, when I was 12, I received a paint by number set, a craft item wildly popular at the time. I began painting immediately and loved seeing a recognizable painting emerge as a result of following … Read more
With 20,000 diagnoses each year, ovarian cancer is the ninth most common cancer and fifth leading cause of cancer death among women in the United States. So many women die from ovarian cancer because it often goes undetected until it … Read more
The life of an athletic 14-year-old girl: school, track practice, gymnastics meets. Cancer wasn’t on Kylee Yarnell’s radar until her ovary ruptured while she was practicing on the bars one evening.
“It’s not usual for her to hurt,” said her … Read more
A new study that followed 10,000 women provides more accurate, age-related estimates of the risk of developing breast and ovarian cancer in carriers of mutations of the BRCA1 and BRCA2 genes. It also suggests that family history and the location … Read more
A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.
Researchers believe the drug, which mimics the action of folic acid to enter … Read more
By: Susan Gubar
Because ovarian cancer initiated a stealthy assault before I discovered it, it seems the clear aggressor, and I the injured party. Yet as my physicians use their weapons to counterattack, collateral damages mount. Fatigue envelops me.
Sometimes … Read more
The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more
With 38,000 oncologists converging on the sprawling McCormick Place for the annual meeting of the American Society of Clinical Oncology, the halls in the convention center are as crowded as Manhattan sidewalks at Christmastime. Watch out or you’ll get run … Read more
By: Annette McElhiney
As an avid reader of any and all material about cancer, my attention was grabbed by the article, “Hope and Hype Around Cancer Immunotherapy.”
Most of us are aware of the excitement currently generated by … Read more
By: Hillary Theakston, Executive Director of The Clearity Foundation
In May, for the first time, the U.S. Food and Drug Administration approved a cancer drug for patients whose tumors are defined by a specific genetic feature (biomarker), rather than by … Read more
The introduction of PARP inhibitors revolutionized the treatment of ovarian cancer, providing much-needed therapeutic options. However, clinical challenges remain as many patients are not candidates for PARP inhibitors and responses are often short-lived. Furthermore, biomarkers have not been established to … Read more
Immunotherapy treatments for cancer are having a moment.
A recent survey of patients with ovarian cancer has found that many of them are uncertain of what to expect after diagnosis, and this uncertainty can be challenging. More than half of the patients (53 percent) surveyed indicated that the … Read more
Colon, pancreatic, stomach, or ovarian cancer; it increasingly shouldn’t matter. In an era of precision medicine, the treatment approach should reflect the genetic makeup of the person’s tumor and the presence or absence of key biomarkers.
That ethos was set … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
